Back to today’s briefing

Story perspectives

AMT-130 Gene Therapy Slows Huntington's Onset by 75%

10/1/2025

50 8

Summary

Story summary

AMT-130 gene therapy for Huntington's disease shows 75% slowdown in onset.
The approach involves a complex brain surgery and targets huntingtin protein.
Findings are preliminary, unreviewed, and may be biased by design and small sample.
If later confirmed safe and effective, AMT-130 could be a breakthrough; more studies before regulatory approval.
Mental health and caregiver support remain crucial.

1 of 1

Story summary

AMT-130 gene therapy for Huntington's disease shows 75% slowdown in onset.
The approach involves a complex brain surgery and targets huntingtin protein.
Findings are preliminary, unreviewed, and may be biased by design and small sample.
If later confirmed safe and effective, AMT-130 could be a breakthrough; more studies before regulatory approval.
Mental health and caregiver support remain crucial.